- Home
- BMRN vs BAX Comparison
BMRN vs BAX Comparison
Compare BMRN & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | BAX |
|---|---|---|
| Founded | 1996 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.2B |
| IPO Year | 1999 | 1994 |
Fundamental Metrics
Financial Performance| Metric | BMRN | BAX |
|---|---|---|
| Price | $59.68 | $17.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 9 |
| Target Price | ★ $87.24 | $22.13 |
| AVG Volume (30 Days) | 2.1M | ★ 9.5M |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 0.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | $1,313,646,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $13.34 | $1.90 |
| Revenue Next Year | $11.42 | $2.09 |
| P/E Ratio | $32.80 | ★ N/A |
| Revenue Growth | ★ 17.62 | 5.72 |
| 52 Week Low | $50.76 | $17.07 |
| 52 Week High | $73.18 | $35.03 |
Technical Indicators
Market Signals| Indicator | BMRN | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 37.42 |
| Support Level | $56.08 | $17.69 |
| Resistance Level | $60.52 | $19.31 |
| Average True Range (ATR) | 2.28 | 0.72 |
| MACD | -0.28 | -0.29 |
| Stochastic Oscillator | 15.11 | 17.89 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.